echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Ansaco 400mg/800mg approved for entry into China

    Ansaco 400mg/800mg approved for entry into China

    • Last Update: 2020-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Pharmaceutical Network, June 5 , Japan's Zeria Group's Tillotts Pharmaceutical Company and Italy's Menarini Group's Menarini International Trade (Wuhan) Co., Ltdjointly announced that the treatment of light moderate ulcerative colitis (UC) first-line drug Ansacol ® (Asacol) 400mg / 800mg approved by the State Drug Administration, officially entered ChinaFollowing the announcement of the partnership by Tillotts and Menarini in October 2019, the approval of Ansaco ® 800mg will be another important milestone for both sides to commercialize China successfullyBased on its two phase III clinical studies in China, Ansaco ® 800mg was submitted for listing several years ago(the original text has a cut)
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.